Tani, Yasuhiro
Ishihara, Ryu
Matsuura, Noriko
Okubo, Yuki
Kawakami, Yushi
Sakurai, Hirohisa
Nakamura, Takahiko
Matsueda, Katsunori
Miyake, Muneaki
Shichijo, Satoki
Maekawa, Akira
Kanesaka, Takashi
Yamamoto, Sachiko
Takeuchi, Yoji
Higashino, Koji
Uedo, Noriya
Michida, Tomoki
Article History
Received: 24 October 2022
Accepted: 30 March 2023
First Online: 28 June 2023
Competing interests
: Satoki Shichijo has received personal fees from Olympus Corporation, Boston Scientific Japan, Daiichi-Sankyo, EA Pharma, AstraZeneca, AI Medical Service Inc, Jannsen Pharmaceutical and Japanese Society of Gastroenterology. Takashi Kanesaka has received personal fees from Olympus Corporation. Yoji Takeuchi has received personal fees from Olympus Corporation, Boston Scientific Japan, FUJIFILM Medical Co., Ltd, Daiichi-Sankyo, Miyarisan Pharmaceutical, Asuka Pharmaceutical, AstraZeneca, EA Pharma, Zeria Pharmaceutical, Kaneka Medix and Kyorin Pharmaceutical. Noriya Uedo has received personal fees from Olympus Corporation, Boston Scientific Japan, FUJIFILM Medical Co., Ltd, Daiichi-Sankyo, Takeda Pharmaceutical, EA Pharma, Otsuka Pharmaceutical, AstraZeneca and Miyarisan Pharmaceutical. Ryu Ishihara has received personal fees from Olympus Corporation, FUJIFILM Medical Co., Ltd, Daiichi-Sankyo, Ono Pharmaceutical, EA Pharma and AstraZeneca. Other authors have no financial relationships to disclose.